LMR Partners’s GSK GSK Stock Holding History

LMR Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51.4M	Hold	980,479	–	–	0.19%	108
2026 Q1	$54.1M	Buy	+980,479	New	+$53.1M	0.12%	89
2025 Q4	–	Sell	-384,302	Closed	-$17.9M	–	1602
2025 Q3	$16.6M	Hold	384,302	–	–	0.07%	208
2025 Q2	$14.8M	Hold	384,302	–	–	0.11%	203
2025 Q1	$14.9M	Hold	384,302	–	–	0.14%	174
2024 Q4	$13M	Sell	384,302 -1,634,890	-81%	-$58.9M	0.11%	188
2024 Q3	$82.5M	Sell	2,019,192 -1,312,266	-39%	-$53.7M	0.66%	23
2024 Q2	$128M	Buy	3,331,458 +2,099,175	+170%	+$88.3M	1.08%	9
2024 Q1	$52.8M	Buy	+1,232,283	New	+$50.8M	0.54%	34
2023 Q3	–	Sell	-10,000	Closed	-$356K	–	978
2023 Q2	$356K	Hold	10,000	–	–	﹤0.01%	532
2023 Q1	$356K	Sell	10,000 -108,571	-92%	-$3.8M	0.01%	772
2022 Q4	$4.17M	Sell	118,571 -228,280	-66%	-$7.6M	0.07%	306
2022 Q3	$10.2M	Buy	+346,851	New	+$13.1M	0.19%	128

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

LMR Partners's GSK Position: Q2 2026 in Review

LMR Partners held its GSK (GSK) position steady in Q2 2026 at 980,479 shares worth $51.4M. The position accounts for 0.19% of the portfolio, ranked #108.

LMR Partners first reported a position in GSK in Q3 2022 and has held it in 13 quarters since. The position peaked at $128M in Q2 2024. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

LMR Partners held 980,479 shares of GSK worth $51.4M as of Q2 2026.
LMR Partners left its GSK share count unchanged in Q2 2026.
GSK made up 0.19% of LMR Partners's portfolio in Q2 2026, its #108 holding.
LMR Partners first reported a position in GSK in Q3 2022 and has held it in 13 quarters since.
LMR Partners's GSK position peaked at $128M in Q2 2024.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.